Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type

Abstract While variant TP53 is an adverse prognosis factor in myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), current clinical prognosis and variation feature analysis of TP53 alterations remain limited. We evaluated 333 MDS/AML patients with TP53 mutations, single nucleotide polymorph...

Full description

Bibliographic Details
Published in:Human Genomics
Main Authors: Xiaodi Yang, Zeyin Liang, Li Ji, Wei Liu, Bingjie Wang, Yuan Li, Jinping Ou, Xinan Cen, Hanyun Ren, Stefan Wuchty, Ziding Zhang, Yujun Dong
Format: Article
Language:English
Published: BMC 2025-08-01
Subjects:
TP53
Gene mutation
MDS/AML
Prognosis
Hematopoietic stem cell transplantation
Online Access:https://doi.org/10.1186/s40246-025-00792-z

Internet

https://doi.org/10.1186/s40246-025-00792-z

Similar Items